anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study follow-up intervals are 6 weeks, 1 year, 2 years, 3 years, 5 years, and 10 years. Demographic data is collected pre-operatively along with the Harris Hip Score and UCLA Activity Score. Operative information includes the surgical technique and other standard operative information. Follow-up information includes the Harris Hip Score, UCLA Activity Score, and Radiographic data. Anterior/posterior and frog leg lateral X-ray data is recorded to show radiolucencies, component position and angles. Sites are also required to send in an Anterior/Posterior Pelvis x-ray for wear analysis. Implant durability is documented by asking the surgeon to record revisions, complications, and device related adverse events. All information collected is de-identified in compliance with HIPAA regulations.
Control group participants will receive a pamphlet providing information on sleep hygiene that matches the information in CBT-I arm (e.g., having a bedtime routine, maintaining a sleep schedule, avoiding exercise within several hours of bed, avoiding bright screens before bed). Otherwise, they will be encouraged to continue with treatment they are receiving, if any. After the 19 week follow-up assessment, participants have the option of receiving the digitized CBT-I intervention.
1. Liposome preparation of compound 6,9-bis-[(2-aminoethyl)amino]benzo[g]isoquinolin-5,10-dione dimaleate (BBR 2778) of formula: characterized in that said liposomes include phosphatidylcholine, cholesterol and compound BBR 2778 in a cholesterol/phospholipid 1:2 to 1:7 weight ratio and in a BBR 2778/phospholipid 1:4 to 1:25 weight ratio. 2. Liposome preparation as claimed in claim 1, wherein said phosphatidylcholine comprises residues of fatty acids selected from palmitic, oleic, linoleic, gamma linoleic, linolenic and stearic acids. 3. Liposome preparation as claimed in claim 1, wherein said phosphatidylcholine is a mixture of the hydrogenated and non-hydrogenated forms in a 1:2 to 2:1 weight ratio. 4. Liposome preparation as claimed in claim 3, wherein said hydrogenated form has melting point 120 degree C and crystallization point 90 degree C, and said non-hydrogenated form has a thermogram substantially as reported in Fig. 5. 5. Liposome preparation as claimed in any one of the above claims, wherein liposomes further comprise stearylamine and/or dicetyl phosphate. 6. The use of the liposome preparation of claims 1-5 for the preparation of an antitumor drug.
BACKGROUND: Constipation is a common adverse effect of antipsychotics, but little investigation has been conducted. We aimed to address the factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20-year period.
METHODS: We enrolled patients with schizophrenia attending each hospital (n = 14) from April 1, 2021, and retrospectively examined all prescriptions as of April 1, 2016, 2011, 2006, and 2001, every 5 years starting in 2021, for this population. 716 participants with complete data were included in the analysis. The Cochran Q test followed by Bonferroni correction and the Cochran-Armitage trend test were used to determine the differences and trends of the frequency of each laxative. Multivariate logistic regression analysis was performed to assess the factors on the initiation of laxative use over a 20-year period.
RESULTS: Of the patients, 25.1% were treated with laxatives in 2001, and 34.1% were treated in 2021. The numbers of patients treated with any laxatives significantly differed over the 20-year period, with a significant increasing trend. In all laxatives, the numbers of patients treated with magnesium oxide, lubiprostone and elobixibat differed with a significant increasing trend. Female sex, age, the total DZP equivalent dose, and the doses of levomepromazine maleate, olanzapine, quetiapine, zotepine, lithium, and carbamazepine in 2021 were significant factors associated with the initiation of laxative use over the 20-year period.
CONCLUSIONS: Careful monitoring is needed for patients treated with levomepromazine maleate, olanzapine, quetiapine and zotepine. Optimizing prescriptions according to treatment guidelines could reduce antipsychotic-induced constipation.
Management of pharyngoesophageal stenosis (PES) after cancer treatment in patients with head and neck cancer (HNC) remains a challenge. The etiology of PES in this group of patients is probably multifactorial, being associated with surgical manipulation, ischemic effects of radiotherapy and even cancer recurrence. It is estimated that up to 50% of patients treated for advanced HNC will present some degree of dysphagia. PES is a frequent cause of post treatment dysphagia of HNC patients. Although the exact prevalence is unknown, several retrospective series estimate that upper cervical stricture is present in 1% to 23% of the cases. The initial approach to PES is endoscopic dilation with a reported success rate ranging from 76% to 96%. In patients with refractory strictures to dilation sessions, endoscopic corticosteroid injection, such as triamcinolone, is usually added to the dilation sessions, which may increase the success of the endoscopic treatment. A relatively small group of patients will be refractory to the association of dilation and corticosteroid injection treatment. Metal stents may be considered in this scenario, but in the case of pharyngoesophageal stenosis, this approach is limited by cervical pain and foreign body sensation. Surgical reconstruction for pharyngoesophageal stenosis refractory to endoscopic treatment is the last therapeutic option (2). Previous radiotherapy, eventual reconstruction with cutaneous flaps make a surgical manipulation of the cervical region a real challenge, with increased adverse event rate, including restenosis.(2) Because of such difficulties, this prospective study aimed to evaluate the efficacy of Mitomycin C (MMC) endoscopic injection for the treatment of pharyngoesophageal stenoses in patients who were treated for head and neck cancer, refractory to endoscopic dilation treatment. There are descriptions of the use of Mitomycin C for scar prevention after ophthalmologic and otorhinolaryngological interventions (8). Its use in endoscopy has previously been described for the treatment of laryngeal and tracheal stenosis as well as refractory esophageal stenosis. Mitomycin C is a substance isolated from the bacterium Streptomyces caespitosus, which is used as a chemotherapeutic agent and has antiproliferative effects on fibroblasts, reducing fibroblast proliferation and collagen formation. Some studies demonstrated the ability to decrease fibroblast activity and consequent scar formation after the application of Mitomycin C on culture of fibroblasts in low concentrations (0.1 to 0.4 mg / ml) for 5 to 10 minutes, affecting their proliferation for over 3 weeks.
It's one of the protective groups.Only the micromotor was used for polishing purposes in the protective treatment groups. 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
OBJECTIVE: To compare the efficacy of isolated off-pump coronary artery bypass grafting (OPCABG) and of coronary artery bypass grafting (CABG) plus mitral valve plasty (MVP) in treating coronary heart disease with moderate ischemic mitral regurgitation to find a better surgical method.
METHODS: Clinical data of 822 patients diagnosed with coronary heart disease and moderate ischemic mitral regurgitation were analyzed retrospectively. Patients were divided into the OPCABG and CABG+MVP groups according to surgical methods. Baseline data of both groups were corrected, and clinical efficacy of the two surgical methods was analyzed and compared using the propensity score inverse probability of treatment weighting (IPTW) method.
RESULTS: There were no significant differences in the use of mammary artery grafts, number of grafts, and blood product consumption between the two groups (P>0.05) after IPTW. However, the CABG+MVP group had a significantly longer operation time than the OPCABG group (4.13 ± 0.85 hours vs. 5.65 ± 1.02 hours, P<0.001). No statistically significant differences in postoperative major adverse cardiac and cerebrovascular events were observed between the two groups. However, the intra-aortic balloon pump rate was higher in the CABG+MVP group than in the OPCABG group (12.3% vs. 25.0%, P=0.012). Although CABG+MVP can improve ischemic mitral regurgitation significantly (95.4% vs. 81.2%, P<0.001), there were no significant differences in the cumulative survival rate and the incidence of major adverse cardiac and cerebrovascular events between the groups (P>0.05) after IPTW.
CONCLUSION: CABG+MVP may not provide more advantage in patients with coronary heart disease and moderate ischemic mitral regurgitation.
272,376. Agopian, L. A. Oct. 25, 1926. Vitamins.-To obtain concentrated forms of vitamin C, vegetable juice, after initial treatment with metal salts such as acetate of lead and copper, as described in Specification 168,903, is given a further treatment, as follows : The filtrate is neutralized with soda until it turns red with cresol red. The precipitate which is formed contains lead and glucosides &c. associated with the vitamin, and by the use of 5 per cent acetic acid the vitamin with a little impurity is brought into solution. Repetition of the treatment with soda and with acetic acid serves to effect further purification and then after elimination of any lead by sulphuretted hydrogen the filtrate is concentrated in vacuo, mixed with milk of lime and ethyl alcohol to remove organic acids &c., and the final filtrate is concentrated to dryness in vacuo. The powder can be dissolved in glycerine and put into capsules. Purer preparations of the vitamin mav be obtained by subjecting the powder to repeated extractions with absolute ethyl alcohol and then to filtrations after admixture with water.
The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
Langerhans cell histiocytosis (LCH) is a rare disorder characterized by the abnormal proliferation of Langerhans cells, a type of immune cell that is normally present in the skin and various other tissues. LCH can affect people of any age but is most commonly diagnosed in children. We report a case of a patient with LCH who developed ipsilateral axillary lymphadenopathology post-COVID-19 vaccination. Lymph node biopsy showed diffuse Langerhans cell hyperplasia which mimicked LCH. Clinically and radiologically, it looked to be a reactive lymph node. The patient was kept on follow up only and after 1 year of follow up the size of lymph nodes regressed confirming to be reactive in nature rather than neoplastic. To the best of our knowledge, this is the second case of Langerhans cell hyperplasia post-COVID-19 vaccination being reported in the literature.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to chemical-pharmaceutical industry, and deals with method of obtaining highly dispersed powders of organic medicinal substances and can be used in manufacturing novel medications. Method of micronosation of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone is realised by the following method. Evapouration of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone is realised in neutral gaseous medium with vacuum 950-10 Pa, and precipitation of its vapours is carried out at rate 1015 - 1017 molec/seccm2 on precipitation surface, which has temperature 120 - 30C, precipitation surface being inclined at angle 15-80 relative to direction of precipitation rate vector, rate of evapouration of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone exceeds rate of their precipitation in 1.2-2.5 times. Also claimed is medication, containing water-dispersive organic medicinal substance in form of micronised powder of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone. ^ EFFECT: elaboration of efficient method of obtaining highly dispersive powders of organic medicinal substances. ^ 2 cl, 2 ex, 2 dwg
NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
As minimally invasive surgery gains grounds, surgeons are switching more towards laparoscopic distal pancreatectomy (LDP) and robotic distal pancreatectomy (RDP) as opposed to open distal pancreatectomy (ODP). Through this study, we aimed at exploring the differences in perioperative and oncologic outcomes among the three surgical methods. We retrospectively collected data from 303 patients who underwent distal pancreatectomy (DP) at a single high-volume institution between June 2015 and December 2021. We equally compared the perioperative and oncologic outcomes in patients who underwent ODP, LDP, and RDP by analyzing clinicopathologic and survival data. We consecutively included 303 cases in the study: open = 147 (48.5%), laparoscopic = 50 (16.5%), and robotic = 106 (35.0%). The median tumor size was significantly larger in the ODP group (P < 0.001) compared to the others. Cases in the RDP group experienced a longer duration of surgery (P < 0.001), smaller amount of blood loss (P < 0.001), smaller amount of blood transfusion (P = 0.042), and a shorter duration of hospital stay (p = 0.040) compared to cases in the ODP group. There was no significant difference observed when comparing other postoperative outcomes across the groups. Overall survival (OS) and progression-free survival (PFS) were similar across the significant differences among the three groups. The short-term postoperative and oncologic outcomes observed in the RDP and LDP groups were not inferior to those in the ODP group. The RDP has some perioperative advantages over the ODP. Therefore, RDP and LDP can safely and feasibly be performed in selected pancreatic tumors by experienced pancreatic surgeons.
Participants will receive Treatment H in Treatment Period 1, followed by Treatment G in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
Many patients may feel much more discomfort from their shoulder pain than incision pain . Post laparoscopic shoulder pain is caused by irritation and/or injury of the diaphragm and phrenic nerve by local acidosis and irritative effect of carbon dioxide during pneumoperitoneum or distention forces on the diaphragm. Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor antidepressant . It is used to treat major depressive disorder in adults. Duloxetine is also used to treat general anxiety disorder. It is also used in adults to treat fibromyalgia (a chronic pain disorder), or chronic muscle or joint pain (such as low back pain and osteoarthritis pain). Duloxetine is also used to treat diabetic neuropathy. Previous studies focused on the use of gabapentin and pregabalin (both are antineuropathic pain medications) to prevent post laparoscopic shoulder pain after laparoscopic ovarian cystectomy and laparoscopic cholecystectomy showed favorable results and since duloxetine is an antineuropathic pain medications we assume its use will ameliorate diaphragmatic irritation and hencepost laparoscopic shoulder pain.
Daily exercise program involved "Range of Motion (ROM) exercises against extremity resistances" and "extension and flexion in upper and lower extremities." Exercises were implemented on wrists, elbows, shoulders, ankles, knees, and hip joints of the infants by the same researcher (YSE). The daily exercise program was repeated 5-8 times, 1 session/day (a similar time of the day), for 30 days. Each session continued for 7-10 minutes.
The process comprises reaction of cyclohexanone of formula (II) with a sodium azide in strong acid medium to give a cpd. of formula (III). This then undergoes N-alkylation and reduction to give cpd. of formula (I). R and R1 are lower alkyls and R2 is hydrogen or aroyl. The prod. is treated with acid to give pharmacologically acceptable salts such as hydrochlorate or hydrocromate.
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
<P>PROBLEM TO BE SOLVED: To develop an external preparation for the skin free from irritation and unpleasant odor, excellent in storage property and antimicrobial properties and increasing a moisture-retaining property and a heat-insulating property.   <P>SOLUTION: The external preparation for skin is obtained by dissolving seaweed in an aqueous solution of a monovalent alkali to provide paste and neutralizing the paste. The monovalent alkali is preferably sodium carbonate. Oil, mineral water, an essential oil and/or a clay mineral may be added thereto. The sodium concentration is preferably 1.4-2.1 and the oil is preferably contained in an amount of 2-10% based on total amount. The external preparation for skin may be used as a pack cosmetic.  <P>COPYRIGHT: (C)2004,JPO
Phase I Dose Level 1 participants receive MLN0128 3 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
The invention discloses a composite skin cream for preventing hands and feet from chapping and a preparation method thereof, and relates to a skin cream and a preparation method thereof. The invention aims to solve the technical problems of poor effect and limited use of the existing rhagadia cream. The compound skin cream is prepared from 1-3 parts of hyaluronic acid, 5-7 parts of eucommia ulmoides extract, 3-7 parts of vitamin E, 2-5 parts of lavender essential oil and 5-8 parts of pure water by mass. The preparation method comprises the following steps: firstly, hyaluronic acid and eucommia ulmoides extracts are uniformly mixed, then vitamin E and lavender essential oil are added, the mixture is uniformly mixed, finally, pure water is added, the mixture is uniformly mixed again to obtain a mixture, and finally, the mixture is homogenized to obtain the composite skin cream for preventing hands and feet from chapping. The composite skin cream has good stability and long shelf life of 2-3 years. Can promote cell growth, improve microcirculation and enable chapped wounds to heal quickly within 3-7. Can be used for skin health protection products or labor protection products.
PURPOSE:To obtain a powdery cleaning composition for washing human body, containing an oil component, medicinal plant component and casein component without containing any surfactant, exhibiting cleaning effect in short time, having excellent skin-preventing effect and capable of continuously separating an aged keratin while protecting the skin. CONSTITUTION:1-15wt% oil component (e.g. yolk lecithin) is blended with 10-40wt% medicinal plant component (e.g. confrey powder) and 5-35wt% casein compound (e.g. caseinate) based the total composition to provide the aimed product. A powder included with cyclodextrin as the oil component and powder obtained by drying a medicinal plant as the medicinal plant component are preferably used. The aimed composition may contain kaolin, talc, starches, etc., in addition to above-mentioned three components, but any addition of a surfactant should be entirely avoided. The addition of a preservative harmful to the skin is not required, since the composition is difficult to decay because it is a powder.
Alcohol-associated liver disease poses a significant global health burden, with rising alcohol consumption and prevalence of alcohol use disorder (AUD) contributing to increased morbidity and mortality. This review examines the challenges and opportunities in the care of candidates and recipients of liver transplant (LT) with AUD. Despite advancements in posttransplant patient survival, the risk of disease recurrence and alcohol relapse remains substantial. Several challenges have been identified, including (1) rising disease burden of alcohol-associated liver disease, variable transplant practices, and systemic barriers; (2) disparities in mental health therapy access and the impact on transplant; (3) variable definitions, underdiagnosis, and stigma affecting access to care; and (4) post-LT relapse, its risk factors, and consequential harm. The review focuses on the opportunities to improve AUD care for candidates and recipients of LT through effective biochemical monitoring, behavioral and pharmacologic approaches, creating Centers of Excellence for post-LT AUD care, advocating for policy reforms, and ensuring insurance coverage for necessary services as essential steps toward improving patient outcomes. The review also highlights unmet needs, such as the scarcity of addiction specialists, and calls for further research on personalized behavioral treatments, digital health, and value-based care models to optimize AUD care in the LT setting.
1,179,384. Therapeutic glycoprotein. TEIKOKU HORMONE MFG. CO. Ltd. 27 March, 1968 [29 March, 1967; 15 March, 1968], No. 14679/68. Heading A5B. A glycoprotein having gastric acid secretion-inhibiting and anti-ulcerative activity is obtained from animal saliva or saliva-producing glands by acidifying an aqueous extract thereof to eliminate proteins having isoelectric points in the regions pH 4-4.6 and 5.4-5.6, adding a water soluble zinc salt to the mother liquor, collecting the precipitate, adding to it in an aqueous solution of a zinc-chelating agent (e.g. sodium citrate, EDTA or glycine), redissolving the precipitate in an aqueous medium, dialysing the solution to remove the zinc chelate and fractionally precipitating the active material either by addition of ammonium sulphate or a water-mixible organic solvent e.g. ethanol or acetone. The active substance may be further purified by conventional procedures (gel-filtration, chromatography &c) and incorporated into compositions for pharmaceutical use.